Effective Treatment for Recurrent Ovarian Cancer Guided by Drug Sensitivity from Ascites-Derived Organoid: A Case Report

Overview

Journal Int J Womens Health

Publisher Dove Medical Press

Specialty Gynecology & Obstetrics

Date 2023 Jul 19

PMID 37465723

Authors

Wanyi Chen

Po-Han Fang

Bin Zheng

Yue Liang

Yiwen Mao

Xuefeng Jiang

Qionglan Tang

Affiliations

Soon will be listed here.

Abstract

So far, ovarian cancer has still been the most lethal gynecological malignancy. The chemotherapy and targeted medication are the mainstay for the recurrent ovarian cancer treatment. About 70% of the advanced-stage cases will relapse. Ascites-derived organoid is a pre-clinical model for the precise prediction of the therapeutic effectiveness for the ovarian cancer: it can be used to assess the drug sensitivity, to guide individualized precise treatment, and to improve advanced stage as well as recurrent ovarian cancer patient' survival and prognosis. Until now, there has been no report concerning the establishment of the organoid out of the patient's ascites and the concurrent usage of drug sensitivity test to guide the individualized precise treatment for the ovarian cancer. Here, we report a case of recurrent ovarian cancer of a 59-year-old female patient whose CA125 at its peak increased to 4523.4 U/mL. Then, patient's own ovarian cancer organoid was constructed from the ascites by the abdominocentesis; concurrently, medication sensitivity test was performed on the organoid to guide individualized precise treatment. After the treatment, CA125 decreased to 33.7 U/mL, and the patient's condition relieved effectively. This is the first published case report using ascites-derived organoid and the drug sensitivity test thereof to guide the precise treatment of recurrent ovarian cancer.

Citing Articles

Organoid development and applications in gynecological cancers: the new stage of tumor treatment.

Li Y, Qin M, Liu N, Zhang C J Nanobiotechnology. 2025; 23(1):20.

PMID: 39819668 PMC: 11740664. DOI: 10.1186/s12951-024-03086-z.

Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.

Hu H, Sun C, Chen J, Li Z J Cancer Res Clin Oncol. 2024; 150(3):146.

PMID: 38509422 PMC: 10955023. DOI: 10.1007/s00432-024-05654-0.

References

Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B . Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 2019; 21(8):1041-1051. DOI: 10.1038/s41556-019-0360-z. View

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

Pavlidis N, Rassy E, Vermorken J, Assi T, Kattan J, Boussios S . The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021; 75:102045. DOI: 10.1016/j.canep.2021.102045. View

Armstrong D, Alvarez R, Bakkum-Gamez J, Barroilhet L, Behbakht K, Berchuck A . NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw. 2019; 17(8):896-909. DOI: 10.6004/jnccn.2019.0039. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Maenhoudt N, Defraye C, Boretto M, Jan Z, Heremans R, Boeckx B . Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models. Stem Cell Reports. 2020; 14(4):717-729. PMC: 7160357. DOI: 10.1016/j.stemcr.2020.03.004. View

Wu Y, Li K, Li Y, Sun T, Liu C, Dong C . Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids. Nucleic Acids Res. 2021; 50(5):e28. PMC: 8934649. DOI: 10.1093/nar/gkab1201. View

Wan C, Keany M, Dong H, Al-Alem L, Pandya U, Lazo S . Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2020; 81(1):158-173. PMC: 7878408. DOI: 10.1158/0008-5472.CAN-20-1674. View

Oronsky B, Ray C, Spira A, Trepel J, Carter C, Cottrill H . A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 2017; 34(6):103. DOI: 10.1007/s12032-017-0960-z. View

10.

Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F . A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2017; 172(1-2):373-386.e10. DOI: 10.1016/j.cell.2017.11.010. View

11.

Rahmanian M, Seyfoori A, Ghasemi M, Shamsi M, Kolahchi A, Modarres H . In-vitro tumor microenvironment models containing physical and biological barriers for modelling multidrug resistance mechanisms and multidrug delivery strategies. J Control Release. 2021; 334:164-177. DOI: 10.1016/j.jconrel.2021.04.024. View

12.

Broutier L, Mastrogiovanni G, Verstegen M, Francies H, Morrill Gavarro L, Bradshaw C . Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017; 23(12):1424-1435. PMC: 5722201. DOI: 10.1038/nm.4438. View

13.

Pujade-Lauraine E, Banerjee S, Pignata S . Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives. J Clin Oncol. 2019; 37(27):2437-2448. DOI: 10.1200/JCO.19.00194. View

14.

Workman M, Mahe M, Trisno S, Poling H, Watson C, Sundaram N . Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system. Nat Med. 2016; 23(1):49-59. PMC: 5562951. DOI: 10.1038/nm.4233. View

15.

Krieger T, Le Blanc S, Jabs J, Ten F, Ishaque N, Jechow K . Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy. Nat Commun. 2021; 12(1):5826. PMC: 8492851. DOI: 10.1038/s41467-021-26059-4. View

16.

Lee S, Hu W, Matulay J, Silva M, Owczarek T, Kim K . Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell. 2018; 173(2):515-528.e17. PMC: 5890941. DOI: 10.1016/j.cell.2018.03.017. View

17.

Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M . Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci Rep. 2020; 10(1):12581. PMC: 7387538. DOI: 10.1038/s41598-020-69488-9. View

18.

Cheung A, Shah S, Parker J, Soor P, Limbu A, Sheriff M . Non-Epithelial Ovarian Cancers: How Much Do We Really Know?. Int J Environ Res Public Health. 2022; 19(3). PMC: 8834485. DOI: 10.3390/ijerph19031106. View

19.

Koshiyama M, Matsumura N, Konishi I . Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014; 2014:934261. PMC: 4017729. DOI: 10.1155/2014/934261. View

20.

Boussios S, Rassy E, Moschetta M, Ghose A, Adeleke S, Sanchez E . BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. Cancers (Basel). 2022; 14(16). PMC: 9405840. DOI: 10.3390/cancers14163888. View